



Aviragen Therapeutics, Inc.
Investor Relations Department
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: AVIR

Last Trade:	0.59
Trade Time:	4:00 PM ET Dec 8, 2017
Change:	0.00 (0.034%)
Day Range	0.58 - 0.60
52-Week Range	0.43 - 1.50
Volume	65,286

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: varendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplatovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papill... [\(more\)](#)

Stock Information



Press Releases [\[View all \]](#)

- Nov 29, 2017
[Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir \(BTA074\) for the Treatment of Condyloma](#)
- Nov 2, 2017
[Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results](#)
- Oct 30, 2017
[Aviragen Therapeutics and Vaxart Enter into Merger Agreement](#)
- Aug 31, 2017
[Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results](#)
- May 4, 2017
[Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Sep 1, 2017
[Annual Report \(10-K\)](#)
- Sep 27, 2016
[Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017
[Quarterly Report \(10-Q\)](#)
- May 8, 2017
[Quarterly Report \(10-Q\)](#)
- Feb 6, 2017
[Quarterly Report \(10-Q\)](#)